SCHEMBL1009470

SCHEMBL1009470

O=c1ccc(Oc2ccccc2)n[nH]1

nearest known ligand 0.48

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 2/20 0.48
NPSR1 Q6W5P4 2/20 0.48
MEN1 O00255 1/20 0.48
MAPK1 P28482 1/20 0.48
KMT2A Q03164 1/20 0.48
HAO1 Q9UJM8 1/20 0.47
KDM4E B2RXH2 3/20 0.46
NPC1 O15118 1/20 0.46
RAB9A P51151 1/20 0.46
ALDH1A1 P00352 3/20 0.45
HPGD P15428 2/20 0.45
TSHR P16473 1/20 0.45
LMNA P02545 2/20 0.43
AKR1B1 P15121 1/20 0.43
USP2 O75604 1/20 0.43
BCAT2 O15382 1/20 0.43
KDR P35968 1/20 0.42
GAA P10253 1/20 0.42
CYP2C19 P33261 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11426027 0.81 KDM4E (0.51) NPSR1MEN1KMT2AHAO1KDM4E
SCHEMBL11427461 0.75 KDM4E (0.49) CYP1A2NPSR1MEN1MAPK1KMT2A
SCHEMBL11146636 0.75 CYP1A2 (0.71) CYP1A2MEN1KMT2ANPC1RAB9A
SCHEMBL2152461 0.74 LMNA (0.51) CYP1A2NPSR1MAPK1KMT2AKDM4E
SCHEMBL4591131 0.73 PKM (0.50) CYP1A2NPSR1MEN1MAPK1KMT2A
SCHEMBL3169378 0.73 CYP1A2 (0.53) CYP1A2MEN1KMT2ALMNA
SCHEMBL3159466 0.72 CYP1A2 (0.65) CYP1A2MEN1MAPK1KMT2AHPGD
SCHEMBL6134199 0.71
SCHEMBL207642 0.71 HAO1 (0.53) CYP1A2MEN1MAPK1KMT2AHAO1
SCHEMBL21995641 0.71 HPGDS (0.61) CYP1A2MEN1KMT2ANPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025215121-A1 HEDGEHOG ACYLTRANSFERASE INHIBITORS IMPERIAL COLLEGE INNOVATIONS LIMITED (GB) 2025-10-16 WO disclosed
US-9376426-B2 Pyridazinone derivatives MERCK PATENT GMBH (DE) 2016-06-28 US disclosed
US-9376426-B2 Pyridazinone derivatives MERCK PATENT GMBH (DE) 2016-06-28 US disclosed
US-9376426-B2 Pyridazinone derivatives MERCK PATENT GMBH (DE) 2016-06-28 US disclosed
US-8853211-B2 Pyridazinone derivatives MERCK PATENT GMBH (DE) 2014-10-07 US disclosed
US-8853211-B2 Pyridazinone derivatives MERCK PATENT GMBH (DE) 2014-10-07 US disclosed
US-8853211-B2 Pyridazinone derivatives MERCK PATENT GMBH (DE) 2014-10-07 US disclosed
US-20140148463-A1 PYRIDAZINONE DERIVATIVES MERCK PATENT GMBH (DE) 2014-05-29 US disclosed
US-20140148463-A1 PYRIDAZINONE DERIVATIVES MERCK PATENT GMBH (DE) 2014-05-29 US disclosed
US-20140148463-A1 PYRIDAZINONE DERIVATIVES MERCK PATENT GMBH (DE) 2014-05-29 US disclosed
US-20110269765-A1 Pyridazinone derivatives MERCK PATENT GMBH (DE) 2011-11-03 US disclosed
US-20110269765-A1 Pyridazinone derivatives MERCK PATENT GMBH (DE) 2011-11-03 US disclosed
US-20110269765-A1 Pyridazinone derivatives MERCK PATENT GMBH (DE) 2011-11-03 US disclosed
EP-2373644-A1 PYRIDAZINONE DERIVATIVES Merck Patent GmbH (DE) 2011-10-12 EP disclosed
EP-2268633-A1 PYRIDAZINONE GLUCOKINASE ACTIVATORS F. Hoffmann-La Roche AG (CH) 2011-01-05 EP disclosed
WO-2010078910-A1 PYRIDAZINONE DERIVATIVES MERCK PATENT GMBH (DE) 2010-07-15 WO disclosed
WO-2010078910-A1 PYRIDAZINONE DERIVATIVES MERCK PATENT GMBH (DE) 2010-07-15 WO disclosed
US-20090264434-A1 PYRIDAZINONE GLUCOKINASE ACTIVATORS BERTHEL STEVEN JOSEPH 2009-10-22 US disclosed
WO-2009127544-A1 PYRIDAZINONE GLUCOKINASE ACTIVATORS F. HOFFMANN-LA ROCHE AG (CH) 2009-10-22 WO disclosed
US-4188388-A Phenoxy pyridazinones and anorexigenic use thereof ALBERT ROLLAND S.A. (FR) 1980-02-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140148463-A1 PYRIDAZINONE DERIVATIVES MET, RET, ERBB2 CYP1A2 727/4885NPSR1 1227/4885MEN1 164/4885
US-20090264434-A1 PYRIDAZINONE GLUCOKINASE ACTIVATORS GCK, GCKR, PDXK CYP1A2 651/4885NPSR1 4397/4885MEN1 3170/4885
US-20110269765-A1 Pyridazinone derivatives MET, RET, ERBB2 CYP1A2 727/4885NPSR1 1227/4885MEN1 164/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.